Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin

Shtemenko, A. V.; Collery, Philippe; Штеменко, Н. И.; Domasevitch, Konstantin V.; Zabitskaya, Elena D.; Golichenko, A. A.

doi:10.1039/b821041a

Cited by 55 publications

(76 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was demonstrated in animal models with tumor-bearing rats, as was a synergism between cisplatin and Re (III) diadamantate (22) and with dichlorotetra-μ-isobutyratodirhenium (III) complex (23) and the cluster Re compound with gamma-aminobutyric acid ligand (24). This synergism was however not observed with the Re (I)-diselenoether complex (4,3), but the schedule of treatments were different.…”

mentioning

confidence: 88%

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Collery

Santoni

Ciccolini

et al. 2016

Self Cite

View full text Add to dashboard Cite

Abstract. Rhenium (I)-diselenoether has shown promising antiproliferative efficacy in both in vitro and in vivo models. However, the maximal tolerated dose and dose-effect relationships have not been fully addressed for this compound. Here, we evaluated the tolerance and efficacy of three dose-levels (namely 10, 40 and 100 mg/kg) intraperitoneally administered daily over 28 days in mice bearing the resistant MDA-MB231 breast cancer cell line.The upper dose was found to be toxic and was reduced to 60 mg/kg. The 10 mg/kg dose well tolerated, whereas 40 mg/kg was associated with 10% mortality (LD 10 ). Both 10 and 40 mg/kg dosing achieved a significantly similar regression of tumor growth compared with untreated animals. This study suggests that 10 mg/kg daily is the recommended dose for rhenium (I) diselenoether.Rhenium(I)-diselenoether has been proposed as an anticancer agent (1-6). This compound features a central atom of rhenium bound to 3,7-diselenanonanedioic acid ligand in which the two selenium atoms secure a tight complexation of the Re, while the carboxylic group, as sodium salt, allows water solubility. This amphiphilic complex is a hydrophilic drug, soluble in water, easy to administer and lipophilic with a good distribution in tissues after oral administration (2).Re is a heavy transition metal (atomic number 75, atomic mass 186.21 g/mol), with the widest range of oxidation states of any element (−3, −1, +1, +2, +3, +4, +5, +6 +7), providing it with unique properties. It was demonstrated with Re-diselenoether drug that Re formed DNA adducts with one or two guanine bases (3), like cisplatin, but with an octahedral configuration and not a square-planar one. The uptake of Re in the nucleus of malignant cells has also been demonstrated after exposure to Re-diselenoether complex (2). Other Re-based drugs have also shown a high activity against a variety of tumor cell lines, with a good selectivity for cancer cells (7,8). One common mechanism of action could be related to the binding of Re with guanine and adenine bases of DNA (9-12). In contrast with cisplatin, the binding with the DNA bases is reversible (13). Re also binds with proteins (14,15). However, other properties of Re compounds have been identified, like the inhibition of some cysteine proteases (16). We hypothesize that the Re atom could be used either for oxidation or reduction of cell components due to its great number of oxidation states. Re cluster compounds were screened for their biological activities as antioxidants (17) and proposed to protect erythrocytes from hemolytic anemia (18). These Re compounds affected the peroxidation level, the activity of superoxide dismutase, the antioxidant factor and the index of resistance of erythrocytes to hemolysis as a function of the concentration range in the pre-incubation medium of erythrocytes (19,20 (22) and with dichlorotetra-μ-isobutyratodirhenium (III) complex (23) and the cluster Re compound with gamma-aminobutyric acid ligand (24). This synergism was however not observed with the Re (I)-di...

show abstract

mentioning

confidence: 88%

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Collery

Santoni

Ciccolini

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…-Earlier, a dirhenium cluster compound with propanoate ligands was found to be active against some types of cancer [12]. These investigators and, later, we [4] found that such compounds decomposed readily into insoluble Re oxides, found in high quantities in the peritoneal cavity of experimental animals, therefore, requiring a considerable amount to be injected so that any significant quantity can reach tumor sites. Use of liposomal forms of dirhenium cluster compounds allowed us to overcome these disadvantages and to elaborate a rather effective antitumor therapy [4] [13].…”

mentioning

confidence: 95%

Liposomal Forms of Rhenium Cluster Compounds: Enhancement of Biological Activity

Штеменко

Zabitskaya

Berzenina

et al. 2008

Chemistry & Biodiversity

View full text Add to dashboard Cite

Liposomal formulations of dinuclear cluster rhenium (Re) compounds were used in biochemical trials. Interaction of liposomal forms of some Re compounds with red blood cells in experiments in vitro showed strong cell-stabilizing properties. In the models of tumor growth and hemolytic anemia in vivo, liposomal forms had better therapeutic effects in comparison with their solutions. The process of formation of liposomes of cluster Re compounds with different organic ligands was investigated by the method of electronic absorption spectra and mechanism of their interactions with lipids is proposed. Encapsulation of cluster Re compounds to lipid coating may have activation significance for the quadruple Re-Re bond.

show abstract

“…4, C) [54]. This may find further applications for the development of new antitumor dirhenium(III) species with active ligands.…”

Section: Fig 3 Volumes Of Tumors In Experiments Withmentioning

confidence: 99%

“…The description of our experiments is also presented, details you may find in [44,49,[53][54][55][56].…”

Section: Anticancer Activity Of Dirhenium Clusters and Work Of The Rhmentioning

confidence: 99%

See 1 more Smart Citation

Rhenium–platinum antitumor systems

Shtemenko¹,

Штеменко²

2017

Ukr.Biochem.J.

View full text Add to dashboard Cite

this review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium (III) design of quadruple bonded dirhenium(III) clusters, their spectral and antiradical properties (in short); interaction of the dirhenium(III) compounds with lipids and formation of liposomes; interaction of the dirhenium(III) compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia; anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system; antianemic and antioxidant properties of the dirhenium(III) compounds in the model of tumor growth; interaction

show abstract

Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin

Cited by 55 publications

References 32 publications

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Liposomal Forms of Rhenium Cluster Compounds: Enhancement of Biological Activity

Rhenium–platinum antitumor systems

Contact Info

Product

Resources

About